Abstract
Background
High-volume hospitals are associated with improved outcomes in glioblastoma (GBM). However, the impact of travel burden to high-volume centers is poorly understood. We examined post-operative outcomes between GBM patients that underwent treatment at local, low-volume hospitals with those that traveled long distances to high-volume hospitals.
Methods
The National Cancer Database was queried for GBM patients that underwent surgery (2010–2014). We established two cohorts: patients in the lowest quartile of travel distance and volume (Short-travel/Low-Volume: STLV) and patients in the highest quartile of travel and volume (Long-travel/High-Volume: LTHV). Outcomes analyzed were 30-day, 90-day mortality, overall survival, 30-day readmission, and hospital length of stay.
Results
Of 35,529 cases, STLV patients (n = 3414) traveled a median of 3 miles (Interquartile range [IQR] 1.8–4.2) to low-volume centers (5 [3–7] annual cases) and LTHV patients (n = 3808) traveled a median of 62 miles [44.1–111.3] to high-volume centers (48 [42–71]). LTHV patients were younger, had lower Charlson scores, largely received care at academic centers (84.4% vs 11.9%), were less likely to be minorities (8.1% vs 17.1%) or underinsured (6.9% vs 12.1), and were more likely to receive trimodality therapy (75.6% vs 69.2%; all p < 0.001). On adjusted analysis, LTHV predicted improved overall survival (HR 0.87, p = 0.002), decreased 90-day mortality (OR 0.72, p = 0.019), lower 30-day readmission (OR 0.42, p < 0.001), and shorter hospitalizations (RR 0.79, p < 0.001).
Conclusions
Glioblastoma patients who travel farther to high-volume centers have superior post-operative outcomes compared to patients who receive treatment locally at low-volume centers. Strategies that facilitate patient travel to high-volume hospitals may improve outcomes.
Similar content being viewed by others
References
Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol 14(Suppl 5):v1–49. https://doi.org/10.1093/neuonc/nos218
Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M (2006) Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2:494–503. https://doi.org/10.1038/ncpneuro0289 (quiz 491 p following 516)
Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190–198. https://doi.org/10.3171/jns.2001.95.2.0190
Omuro A, DeAngelis LM (2013) Glioblastoma and other malignant gliomas: a clinical review. JAMA 310:1842–1850. https://doi.org/10.1001/jama.2013.280319
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330
Begg CB, Cramer LD, Hoskins WJ, Brennan MF (1998) Impact of hospital volume on operative mortality for major cancer surgery. JAMA 280:1747–1751
Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, Welch HG, Wennberg DE (2002) Hospital volume and surgical mortality in the United States. N Engl J Med 346:1128–1137. https://doi.org/10.1056/NEJMsa012337
Barker FG 2nd, Curry WT Jr, Carter BS (2005) Surgery for primary supratentorial brain tumors in the United States, 1988 to 2000: the effect of provider caseload and centralization of care. Neuro Oncol 7:49–63. https://doi.org/10.1215/s1152851704000146
Cowan JA Jr, Dimick JB, Leveque JC, Thompson BG, Upchurch GR Jr, Hoff JT (2003) The impact of provider volume on mortality after intracranial tumor resection. Neurosurgery 52:48–53 (discussion 53–44)
Hauser A, Dutta SW, Showalter TN, Sheehan JP, Grover S, Trifiletti DM (2018) Impact of academic facility type and volume on post-surgical outcomes following diagnosis of glioblastoma. J Clin Neurosci 47:103–110. https://doi.org/10.1016/j.jocn.2017.10.087
Trinh VT, Davies JM, Berger MS (2015) Surgery for primary supratentorial brain tumors in the United States, 2000–2009: effect of provider and hospital caseload on complication rates. J Neurosurg 122:280–296. https://doi.org/10.3171/2014.9.jns131648
Curry WT Jr, Barker FG 2nd (2009) Racial, ethnic and socioeconomic disparities in the treatment of brain tumors. J Neurooncol 93:25–39. https://doi.org/10.1007/s11060-009-9840-5
Mukherjee D, Zaidi HA, Kosztowski T, Chaichana KL, Brem H, Chang DC, Quinones-Hinojosa A (2010) Disparities in access to neuro-oncologic care in the United States. Arch Surg 145:247–253. https://doi.org/10.1001/archsurg.2009.288
Probst JC, Laditka SB, Wang JY, Johnson AO (2007) Effects of residence and race on burden of travel for care: cross sectional analysis of the 2001 US National Household Travel Survey. BMC Health Serv Res 7:40. https://doi.org/10.1186/1472-6963-7-40
Syed ST, Gerber BS, Sharp LK (2013) Traveling towards disease: transportation barriers to health care access. J Community Health 38:976–993. https://doi.org/10.1007/s10900-013-9681-1
National Cancer Database (2017)
Goyal S, Chandwani S, Haffty BG, Demissie K (2015) Effect of travel distance and time to radiotherapy on likelihood of receiving mastectomy. Ann Surg Oncol 22:1095–1101. https://doi.org/10.1245/s10434-014-4093-8
Gunderson CC, Nugent EK, McMeekin DS, Moore KN (2013) Distance traveled for treatment of cervical cancer: who travels the farthest, and does it impact outcome? Int J Gynecol Cancer 23:1099–1103. https://doi.org/10.1097/IGC.0b013e3182989464
Lidsky ME, Sun Z, Nussbaum DP, Adam MA, Speicher PJ, Blazer DG 3rd (2017) Going the extra mile: improved survival for pancreatic cancer patients traveling to high-volume centers. Ann Surg 266:333–338. https://doi.org/10.1097/sla.0000000000001924
Massarweh NN, Chiang YJ, Xing Y, Chang GJ, Haynes AB, You YN, Feig BW, Cormier JN (2014) Association between travel distance and metastatic disease at diagnosis among patients with colon cancer. J Clin Oncol 32:942–948. https://doi.org/10.1200/jco.2013.52.3845
Speicher PJ, Englum BR, Ganapathi AM, Wang X, Hartwig MG, D’Amico TA, Berry MF (2017) Traveling to a high-volume center is associated with improved survival for patients with esophageal cancer. Ann Surg 265:743–749. https://doi.org/10.1097/sla.0000000000001702
Xia L, Taylor BL, Mamtani R, Christodouleas JP, Guzzo TJ (2018) Associations between travel distance, hospital volume, and outcomes following radical cystectomy in patients with muscle-invasive bladder cancer. Urology 114:87–94. https://doi.org/10.1016/j.urology.2017.12.014
Vetterlein MW, Loppenberg B, Karabon P, Dalela D, Jindal T, Sood A, Chun FK, Trinh QD, Menon M, Abdollah F (2017) Impact of travel distance to the treatment facility on overall mortality in US patients with prostate cancer. Cancer 123:3241–3252. https://doi.org/10.1002/cncr.30744
Ward EP, Unkart JT, Bryant A, Murphy J, Blair SL (2017) Influence of distance to hospital and insurance status on the rates of contralateral prophylactic mastectomy, a national cancer data base study. Ann Surg Oncol 24:3038–3047. https://doi.org/10.1245/s10434-017-5985-1
Koshy M, Sher DJ, Spiotto M, Husain Z, Engelhard H, Slavin K, Nicholas MK, Weichselbaum RR, Rusthoven C (2017) Association between hospital volume and receipt of treatment and survival in patients with glioblastoma. J Neurooncol 135:529–534. https://doi.org/10.1007/s11060-017-2598-2
Noorbakhsh A, Tang JA, Marcus LP, McCutcheon B, Gonda DD, Schallhorn CS, Talamini MA, Chang DC, Carter BS, Chen CC (2014) Gross-total resection outcomes in an elderly population with glioblastoma: a SEER-based analysis. J Neurosurg 120:31–39. https://doi.org/10.3171/2013.9.jns13877
Trifiletti DM, Alonso C, Grover S, Fadul CE, Sheehan JP, Showalter TN (2017) Prognostic implications of extent of resection in glioblastoma: analysis from a large database. World Neurosurg 103:330–340. https://doi.org/10.1016/j.wneu.2017.04.035
Brown TJ, Brennan MC, Li M, Church EW, Brandmeir NJ, Rakszawski KL, Patel AS, Rizk EB, Suki D, Sawaya R, Glantz M (2016) Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis. JAMA Oncol 2:1460–1469. https://doi.org/10.1001/jamaoncol.2016.1373
Haque W, Verma V, Butler EB, Teh BS (2017) Definitive chemoradiation at high volume facilities is associated with improved survival in glioblastoma. J Neurooncol 135:173–181. https://doi.org/10.1007/s11060-017-2563-0
Curry WT Jr, Carter BS, Barker FG 2nd (2010) Racial, ethnic, and socioeconomic disparities in patient outcomes after craniotomy for tumor in adult patients in the United States, 1988–2004. Neurosurgery 66:427–437 (discussion 437–428)
Guidry JJ, Aday LA, Zhang D, Winn RJ (1997) Transportation as a barrier to cancer treatment. Cancer Pract 5:361–366
Goossens-Laan CA, Gooiker GA, van Gijn W, Post PN, Bosch JL, Kil PJ, Wouters MW (2011) A systematic review and meta-analysis of the relationship between hospital/surgeon volume and outcome for radical cystectomy: an update for the ongoing debate. Eur Urol 59:775–783. https://doi.org/10.1016/j.eururo.2011.01.037
Funding
The project described was partially supported by the National Institutes of Health, Pre-doctoral Grant TL1TR001443 awarded to MGB and RRS.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Lopez Ramos, C., Brandel, M.G., Steinberg, J.A. et al. The impact of traveling distance and hospital volume on post-surgical outcomes for patients with glioblastoma. J Neurooncol 141, 159–166 (2019). https://doi.org/10.1007/s11060-018-03022-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-018-03022-w